BI 10773 + ethinylestradiol + levonorgestrel

This drug is a fixed-dose **combination therapy** consisting of **empagliflozin (BI 10773)**, **ethinylestradiol**, and **levonorgestrel**. Empagliflozin is a **sodium-glucose co-transporter 2 (SGLT2) inhibitor** that reduces blood glucose by limiting renal glucose reabsorption, primarily indicated for the treatment of type 2 diabetes mellitus[1][2][3][4]. Ethinylestradiol is a synthetic estrogen and levonorgestrel is a synthetic progestin; these two are commonly used together as an oral contraceptive, acting as hormonal agents to inhibit ovulation and alter endometrial and cervical secretions to prevent pregnancy. This particular combination is not a standard formulation, and no clinical data for the fixed combination are found; empagliflozin and oral contraceptives may be co-administered to women requiring both glycemic control and contraception.

Other names

empagliflozin + ethinylestradiol + levonorgestrel